{
    "2019-08-11": [
        [
            {
                "time": "2018-03-15",
                "original_text": "5 Reasons Novartis Shareholders Aren't Shaken",
                "features": {
                    "keywords": [
                        "Novartis",
                        "shareholders",
                        "reasons",
                        "shaken"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-03-15",
                "original_text": "5 Reasons Novartis Shareholders Aren't Shaken",
                "features": {
                    "keywords": [
                        "Novartis",
                        "shareholders",
                        "reasons",
                        "shaken"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-03-15",
                "original_text": "Novartis benefits from faster China drug approvals",
                "features": {
                    "keywords": [
                        "Novartis",
                        "benefits",
                        "faster",
                        "China",
                        "drug",
                        "approvals"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}